Andrew Wieging, MD
Family Medicine · Fort Wayne, INNPI 1689104242
Payments from drug & device makers
Across 491 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$1K
- Novo Nordisk$893
- AbbVie$846
- Boehringer Ingelheim$827
- Axsome Therapeutics, Inc.$420
- plus $4K from 26 others
What the payments were for
- Food & beverage$10,20699%
- Education$661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $2,306 |
| Lilly USA, LLC | 66 | $1,434 |
| Novo Nordisk | 55 | $893 |
| AbbVie | 52 | $846 |
| Boehringer Ingelheim | 47 | $827 |
| Axsome Therapeutics, Inc. | 15 | $420 |
| Amgen(2 entities) | 20 | $411 |
| Bayer | 9 | $316 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $308 |
| Astellas Pharma US Inc | 12 | $308 |
| GSK | 15 | $304 |
| Pfizer | 15 | $244 |
| Vanda Pharmaceuticals Inc. | 10 | $203 |
| Amarin Pharma, Inc. | 12 | $199 |
| Exact Sciences | 11 | $188 |
| Sanofi-aventis U.S. LLC | 10 | $170 |
| Merck | 11 | $170 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $98 |
| Sumitomo Pharma America, Inc. | 5 | $90 |
| Abbott | 5 | $86 |
| Johnson & Johnson | 3 | $51 |
| Corcept Therapeutics | 2 | $43 |
| Amneal Pharmaceuticals LLC | 3 | $40 |
| Insulet Corporation | 2 | $39 |
| Eisai Inc. | 2 | $32 |
| Medtronic | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,272 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 119 | $206,621 |
| JardianceEmpagliflozin | 125 | $175,212 |
| EliquisApixaban | 95 | $126,425 |
| MounjaroTirzepatide | 73 | $102,494 |
| FarxigaDapagliflozin Propanediol | 108 | $93,727 |
| TrulicityDulaglutide | 53 | $81,234 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 64 | $68,713 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $67,607 |
| OtezlaApremilast | 13 | $61,154 |
| VraylarCariprazine Hcl | 20 | $39,071 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $28,641 |
| JanuviaSitagliptin Phosphate | 21 | $24,569 |
| XareltoRivaroxaban | 15 | $22,263 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $22,172 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $19,291 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $893 | $206,621119 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $827 | $188,764140 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,434 | $183,727126 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,306 | $162,440172 claims |
| PfizerEliquis | $244 | $126,42595 claims |
| GSKTrelegy Ellipta | $304 | $67,60770 claims |
| AmgenOtezla | $411 | $61,15413 claims |
| AbbVieVraylar, Linzess | $846 | $53,62932 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $170 | $28,64121 claims |
| MerckJanuvia | $170 | $24,56921 claims |
| Johnson & JohnsonXarelto | $51 | $22,26315 claims |
| Astellas Pharma US IncMyrbetriq | $308 | $16,00315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Fort Wayne
- Thomas KintanarFort Wayne$185K
- Brianna SerbusFort Wayne$174K
- Brian AdamsFort Wayne$173K
- Charles CoatsFort Wayne$38K
- Beulah PenumudiFort Wayne$38K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.